Advertisement
ARRY vs BBIO
Which Stock Would AI Choose? Array Technologies (ARRY) vs. BridgeBio Pharma (BBIO) Stock Comparison
Key Takeaways
- Array Technologies (ARRY), a solar tracker manufacturer, operates in the renewable energy sector, while BridgeBio Pharma (BBIO) develops therapies for genetic diseases in biotechnology.
- ARRY has a market capitalization of approximately $1.2 billion and trades around $8, compared to BBIO's $14.5 billion market cap and $74 share price.
- Year-to-date, ARRY shows a 13% gain, outperforming BBIO's 3% rise, but BBIO leads over one year with 105% versus ARRY's 60%.
- Both stocks report negative earnings per share (EPS), with ARRY at -0.73 and BBIO at -3.78, reflecting growth-stage challenges.
- ARRY faces high debt-to-equity ratio of 294%, while BBIO maintains stronger cash reserves at $587 million.
- Recent market activity shows BBIO gaining momentum from pipeline updates and analyst upgrades, contrasting ARRY's declines amid sector pressures.
Introduction
Array Technologies (ARRY) and BridgeBio Pharma (BBIO) offer a compelling stock comparison for investors navigating volatile growth sectors. ARRY provides solar tracking systems amid renewable energy transitions, while BBIO advances genetic therapies in biotechnology. Traders interested in relative performance, momentum shifts, and sector-specific catalysts will find value here. This analysis highlights recent price behavior, sentiment drivers, and key metrics to inform market positioning decisions in today's dynamic environment.
ARRY Overview and Recent Performance
Array Technologies (ARRY) manufactures solar tracking systems, including single- and dual-row trackers, supporting utility-scale photovoltaic projects globally. The company reported trailing twelve-month (TTM) revenue of $1.28 billion but posted a net loss with EPS of -0.73, pressured by high operating costs and debt levels. In recent market activity, shares have traded around $8, down from a 52-week high of $12.23, underperforming broader indices during gains. Sentiment reflects solar sector headwinds, including supply chain issues and policy uncertainties, contributing to price declines in recent weeks. Year-to-date gains of 13% show resilience, yet volatility persists with a beta of 1.79.
BBIO Overview and Recent Performance
BridgeBio Pharma (BBIO) focuses on precision medicines for genetic diseases, with products like Attruby for amyloidosis and a pipeline including gene therapies. TTM revenue reached $502 million, though losses persist at EPS -3.78 amid R&D investments. Shares recently hovered near $74, up from a 52-week low of $31.77, buoyed by clinical advancements and analyst price target increases to around $100. Recent weeks have seen gains amid biotech optimism, with positive news on pipeline milestones and inducement grants supporting sentiment. One-year returns exceed 105%, though YTD performance lags at 3%.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of top-performing AI trading bots optimized for current market conditions. From Tickeron’s library of over 350 AI trading bots—which scan and trade thousands of tickers across stocks, ETFs, and crypto—the trending section features 25 standout agents. These bots employ diverse strategies, including short-term scalping, swing trading, and long-term trend following, each with unique performance statistics, win rates, and risk profiles tailored to varying timeframes and market volatility. This dynamic ranking highlights bots demonstrating strong adaptability, helping traders identify tools suited to prevailing trends like sector rotations or momentum plays. Explore the Trending AI Robots page to evaluate and potentially deploy these automated strategies.
Head-to-Head Comparison
ARRY’s hardware-centric business model contrasts BBIO’s R&D-heavy drug development, exposing ARRY to energy policy shifts and BBIO to clinical trial outcomes. Growth drivers differ: ARRY benefits from solar demand, while BBIO relies on approvals like those for rare diseases. Recent momentum favors BBIO, with stronger one-year gains and analyst support, versus ARRY’s relative underperformance. Risk factors include ARRY’s elevated debt and BBIO’s pipeline binary events. Sector exposure pits renewables against healthcare, with BBIO showing better market sentiment amid biotech rallies.
Tickeron AI Verdict
Tickeron’s AI currently favors BBIO due to its consistent trend strength, higher analyst price targets implying 35% upside, and pipeline catalysts enhancing relative positioning. While ARRY offers value in renewables, BBIO’s momentum and stability in recent activity suggest greater probabilistic outperformance, subject to market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Hold and BBIO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 1 FA rating(s) are green whileBBIO’s FA Score has 1 green FA rating(s).
- ARRY’s FA Score: 1 green, 4 red.
- BBIO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 7 TA indicator(s) are bullish while BBIO’s TA Score has 3 bullish TA indicator(s).
- ARRY’s TA Score: 7 bullish, 3 bearish.
- BBIO’s TA Score: 3 bullish, 3 bearish.
Price Growth
ARRY (@Alternative Power Generation) experienced а +5.69% price change this week, while BBIO (@Biotechnology) price change was +1.32% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was -3.18%. For the same industry, the average monthly price growth was -6.03%, and the average quarterly price growth was +3.21%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.
Reported Earning Dates
ARRY is expected to report earnings on Aug 11, 2026.
BBIO is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Alternative Power Generation (-3.18% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Biotechnology (+7.11% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ARRY | BBIO | ARRY / BBIO | |
| Capitalization | 1.31B | 13.5B | 10% |
| EBITDA | 29.6M | -535.2M | -6% |
| Gain YTD | -7.375 | -9.923 | 74% |
| P/E Ratio | 56.91 | N/A | - |
| Revenue | 1.21B | 580M | 208% |
| Total Cash | 201M | 940M | 21% |
| Total Debt | 763M | 2.49B | 31% |
ARRY | BBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 85 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 51 | |
P/E GROWTH RATING 1..100 | 32 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 12 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BBIO's Valuation (3) in the null industry is significantly better than the same rating for ARRY (98) in the Biotechnology industry. This means that BBIO’s stock grew significantly faster than ARRY’s over the last 12 months.
BBIO's Profit vs Risk Rating (85) in the null industry is in the same range as ARRY (100) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ARRY’s over the last 12 months.
BBIO's SMR Rating (100) in the null industry is in the same range as ARRY (100) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ARRY’s over the last 12 months.
BBIO's Price Growth Rating (51) in the null industry is in the same range as ARRY (53) in the Biotechnology industry. This means that BBIO’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (32) in the Biotechnology industry is significantly better than the same rating for BBIO (100) in the null industry. This means that ARRY’s stock grew significantly faster than BBIO’s over the last 12 months.
| ARRY | BBIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 85% |
| Advances ODDS (%) | 2 days ago 80% | 19 days ago 80% |
| Declines ODDS (%) | 7 days ago 87% | 22 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 84% | N/A |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 83% |
Advertisement
BBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | +3.97% | ||
| AXON - BBIO | 44% Loosely correlated | -3.16% | ||
| ARRY - BBIO | 43% Loosely correlated | +6.75% | ||
| PMN - BBIO | 43% Loosely correlated | +1.28% | ||
| KURA - BBIO | 41% Loosely correlated | +4.33% | ||
| DYN - BBIO | 39% Loosely correlated | +5.51% | ||
More | ||||